Erschienen in:
31.05.2016 | Editorial
HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy
verfasst von:
Geoffrey Dusheiko, Bo Wang, Ivana Carey
Erschienen in:
Hepatology International
|
Ausgabe 5/2016
Einloggen, um Zugang zu erhalten
Excerpt
Hepatitis B surface antigen (HBsAg) clearance is a relatively rare outcome during the complex natural history of chronic hepatitis B [
1]. The estimated annual incidence of clearance of HBsAg is 1–2 % in Asian and in Western populations [
2]. Annual rates of HBsAg loss in HBeAg-negative patients may be higher in those with lower levels of hepatitis B replication, minimal hepatitis and normal serum aminotransferases [
3]. Hepatitis B genotype and mode of acquisition may influence the rate of HBsAg loss. Spontaneous seroclearance of HBsAg is thought to be beneficial, and to confer an improved outlook; thus HBsAg concentrations and loss may be a useful biomarker of prognosis in patients with chronic hepatitis B [
4]. HBsAg loss may also occur, although relatively rarely, after interferon-alpha treatment or nucleoside analogue anti-viral therapy [
5‐
7]. Likewise, the prognosis is improved, and thus HBsAg loss, rather than merely HBV DNA suppression, has become an important goal of potential curative therapies for hepatitis B. …